Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
posted on
Feb 29, 2024 05:21PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Wow that was a lot lol - only fella here that’s had it all figured out from the get go i guess.Given the insanely pathetic volumes & difficulty buying or selling this thing doubt if there would be room for more than one person to masterfully pull off the day trading success you supposedly had. Ya things could have gone better but that’s no excuse for this ceo. Shares were free lol you can’t take something from one hand & give it to the other & believe you now have more lol Patience you say , theres been plenty of patience over the combined 30 + years for both these company’s. Failed forwarding looking statements at every turn over the last 5 years min have crushed that.Sell & move on you say , some folks are down Pennie’s on the dollar thus being left with holding hopeful the science wins the day regardless of all past mistakes. Not sure why you find it so hard to appreciate peoples frustrations. Sure we don’t all handle it with great patience & grace but it can easily be understood imo. I like everyone else here remains hopeful that things turn at some point, that’s all we have left for goodness sake.Consider showing a little patience & understanding for those who have given witness the last 20/30 year combined history.I'm sure most take responsibility for buying into this , that doesn’t mean we can’t complain about how it’s turned out to this point. Being hit with the same ignorance we’ve received from management isn’t a winning formula imo.GLTA
GLTA